Cui, S., Zhao, Y., Dong, L., Gu, A., Xiong, L., Qian, J., . . . Jiang, L. (2016). Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients. Cancer Med.

Cui, Shaohua, et al. "Is There a Progression‐free Survival Benefit of First‐line Crizotinib Versus Standard Chemotherapy and Second‐line Crizotinib in ALK‐positive Advanced Lung Adenocarcinoma? A retrospective Study of Chinese Patients." Cancer Med 2016.

Cui, Shaohua, et al. "Is There a Progression‐free Survival Benefit of First‐line Crizotinib Versus Standard Chemotherapy and Second‐line Crizotinib in ALK‐positive Advanced Lung Adenocarcinoma? A retrospective Study of Chinese Patients." Cancer Med 2016.